BS
Brijendra Singh
Scientific Consultant, CytomX Therapeutics (United States), Nektar Therapeutics (United States)
Employment
-
Scientific Consultant2024 - Present
-
CytomX Therapeutics (United States) Scientist2023 - 2024
-
Nektar Therapeutics (United States) Scientist2022 - 2023
-
The Children's Hospital of Philadelphia Postdoctoral Research Fellow2017 - 2022
-
University of Pittsburgh Cancer Institute Postdoctoral Associate2016 - 2016
-
Cincinnati Children's Hospital Medical Center Research Fellow2014 - 2016
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (11)
- Lnk deficiency enhances translesion synthesis to alleviate replication stress and promote hematopoietic stem cell fitness. Save
- Lnk/Sh2b3 deficiency restores hematopoietic stem cell function and genome integrity in Fancd2 deficient Fanconi anemia. Save
- Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis. Save
- Regulatory role of CCL5 (rs2280789) and CXCL10 (rs56061981) gene polymorphisms on intracellular CCL5 and CXCL10 expression in pulmonary tuberculosis. Save
- IL-31-Driven Skin Remodeling Involves Epidermal Cell Proliferation and Thickening That Lead to Impaired Skin-Barrier Function. Save
- Th2 Cytokines Augment IL-31/IL-31RA Interactions via STAT6-dependent IL-31RA Expression. Save
- CCL2, CCL3 and CCL4 gene polymorphisms in pulmonary tuberculosis patients of South India. Save
- Effect of vitamin D3 on chemokine expression in pulmonary tuberculosis. Save
- Stromal cell-derived factor-1 (SDF-1/CXCL12) gene polymorphisms in pulmonary tuberculosis patients of south India. Save
- CCL5 (RANTES) gene polymorphisms in pulmonary tuberculosis patients of south India. Save